The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib

Gioacchino Catania, Rita Tavarozzi, Giacomo Maria Pini, Tiziana Borra, Carolina Gandolfo, Giulia Zacchi, Daniela Pietrasanta, Federico Monaco, Manuela Zanni, Maddalena Lettieri, Paolo Rivela, Francesco Zallio, Marco LADETTO

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: The use of Bruton's tyrosine kinase (BTK) inhibitors has changed the clinical history of patients with chronic lymphocytic leukemia (CLL) in both naïve and relapsed/refractory settings. "Accelerated" chronic lymphocytic leukemia (a-CLL) is a relatively rare form of CLL representing less than 1 % of all CLL cases. a-CLL patients usually have a more aggressive course and a reduced overall survival was reported with conventional chemo-immunotherapy approaches. Methods: The role of Bruton Tyrosine Kinase-inhibitor, ibrutinib, in a-CLL is well established with encouraging preliminary results. Results: We report a case of a-CLL-treated first-line with second-generation BTKi, acalabrutinib with a prompt clinical response. As known, it is the first literature report on acalabrutinib in a-CLL highlighting the role of second-generation BTKi also in this high-risk setting. Conclusions: Target therapies (Bruton Kinase inhibitors and Bcl2 inhibitors) have improved the therapeutic landscape of CLL. The availability of therapeutic targets requires greater diagnostic accuracy to choose the most appropriate therapy for each patient.
Original languageEnglish
Pages (from-to)401-404
Number of pages4
JournalJournal of Basic and Clinical Physiology and Pharmacology
Volume34
Issue number3
DOIs
Publication statusPublished - 2023

Keywords

  • Bruton kinase inhibitors
  • leukemia
  • precision medicine
  • target therapy

Fingerprint

Dive into the research topics of 'The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib'. Together they form a unique fingerprint.

Cite this